Showing 4321-4330 of 5957 results for "".
- EyeCheq adds Jai G. Parekh, MD, to its Executive Teamhttps://modernod.com/news/eyecheq-adds-jai-g-parekh-md-mba-to-its-executive-team/2481428/EyeCheq, the developer of a fully autonomous eye screening platform using artificial intelligence (AI), announced that Jai G. Parekh, MD, FAAO, has been named Executive Vice-President and Chief Innovation Officer. Dr. Parekh, a dual-train
- Spectrum Ophthalmics Launches New Range of Dry Eye Productshttps://modernod.com/news/spectrum-ophthalmics-launches-new-range-of-dry-eye-products/2481427/Spectrum Ophthalmics has launched a new range of dry eye products in the UK. The products include the OptiClear IPL for the treatment of dry eye disease (DED), and a 3nethra classic HD fundus camera for the diagnosis of DED. The OptiClear IPL uses light energy to rejuvenate Me
- Belkin Vision’s New Glaucoma Laser Technology Now Available in Germanyhttps://modernod.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/Belkin Vision announced that its Direct SLT Eagle device, an automated, non-contact glaucoma laser treatment, is being used to treat glaucoma patients at The University Eye Clinic in Bochum, Germany. “The Eagle by Belkin Vision will be transformative for many of the esti
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Brent Saunders Returns to Bausch + Lomb as CEO and Chair of the Board of Directorshttps://modernod.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/After nearly a decade, pharma executive Brent Saunders is returning to Bausch + Lomb where he will serve as CEO and Chair of the Board of Directors, effective March 6, 2023. Mr. Saunders served as Bausch + Lomb's CEO from 2010 to 2013 before its sale to Valeant Pharmaceuti
- Visionix Launches Optovue Solix FullRange OCThttps://modernod.com/news/visionix-launches-optovue-solix-fullrange-oct/2481409/Visionix USA has introduced the Optovue Solix FullRange OCT in North America. Featuring 120kHz ultra-high-speed scanning, Optovue Solix FullRange OCT features anterior 18 x 6.25 scans, new posterior high-density scan patterns for more detail and better precision, int
- Ocular Therapeutix Announces Interim Data from the Ongoing US Phase 1 Trial Evaluating OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-data-from-the-ongoing-us-phase-1-trial-evaluating-otx-tki-for-the-treatment-of-wet-amd/2481406/Ocular Therapeutix announced interim 10-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseas
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis for Wet AMD Meets Primary Endpointhttps://modernod.com/news/opthea-phase-2b-trial-results-of-opt-302-in-combination-with-lucentis-for-wet-amd-meets-primary-endpoint/2481405/Opthea announced that the phase 2b study results of OPT-302, the company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), met the prespecified primary efficacy endpoint.
- Eylea Approved as First Pharmacologic Treatment of Preterm Infants with ROPhttps://modernod.com/news/eylea-approved-as-first-pharmacologic-for-treatment-of-preterm-infants-with-rop/2481400/The FDA has approved Eylea (aflibercept) to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, Eylea is now indicated to treat five retinal conditions caused by ocular angiogenesis. “Retinopathy of prematurity is a leadi